General Information
Version
6.3
Revision date
2025-11-03
Product name
Lithium polysilicate solution
Icons in SDS
Company Information
company name
Sigma-Aldrich Chemical Pvt Limited
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H318, H335
Hazard statements
Code
Statements
H318
Causes serious eye damage
Section 2
SECTION 2: Hazards identification
2.1 Classification of the substance or mixture
Serious eye damage, (Category H318: Causes serious eye damage. 1) Specific target organ toxicity - H335: May cause respiratory irritation. single exposure, (Category 3),
Signal word
Danger Danger
Hazard statements
H318 Causes serious eye damage. H335 May cause respiratory irritation. H318 Causes serious eye damage.
Precautionary statements
P261 Avoid breathing mist or vapours. P271 Use only outdoors or in a well-ventilated area. P280 Wear eye protection/ face protection. P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P403 + P233 Store in a well-ventilated place. Keep container tightly closed. P280 Wear eye protection/ face protection. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
Supplemental label elements
none Reduced Labelling (<= 125 ml) none
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
